Pfizer to buy cancer drug developer Array for $10.64 billion

Pfizer Inc said on Monday it would acquire Array Biopharma Inc for $10.64 billion in cash, giving it access to the target’s approved drugs for skin cancer and the targeted cancer medicines in its pipeline.

…read more

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

Source:: Reuters – Business News